AFM
PHIO icon

Anson Funds Management’s Phio Pharmaceuticals PHIO Stock Holding History

Anson Funds Management’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,492
Closed -$120K – 198
2023
Q4 		$120K Buy
+17,492
New +$180K 0.01% 156
2023
Q3 		– Sell
-2,508
Closed -$64.8K – 158
2023
Q2 		$64.8K Buy
+2,508
New +$88.1K 0.01% 141
2016
Q1 		– Sell
-1
Closed -$328K – 75
2015
Q4 		$328K Buy
+1
New +$251K 0.11% 61

Other funds holding PHIO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Anson Funds Management's PHIO Position: Q1 2024 in Review

Anson Funds Management sold out of Phio Pharmaceuticals (PHIO) in Q1 2024, closing a stake of 17,492 shares — an estimated $120K sold.

Anson Funds Management first reported a position in PHIO in Q4 2015 and held it in 3 quarters. The position peaked at $328K in Q4 2015. 10 funds tracked by Wall St. Rank hold PHIO as of Q1 2024.

  • Anson Funds Management reported no remaining Phio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 17,492 Phio Pharmaceuticals shares in Q1 2024, an estimated $120K.
  • Anson Funds Management first reported a position in Phio Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Anson Funds Management's Phio Pharmaceuticals position peaked at $328K in Q4 2015.
  • 10 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.